#### **Supplementary Figures 1-8 and Supplementary Tables 1-2**



Supplementary Figure 1 A) *Ct* values of *Gapdh, Bves,* and *E-cadherin* mRNA levels in WT mouse colons. B) Immunoblot of E-cadherin, BVES and  $\beta$ -actin in mouse colons.



Quantification of cleaved caspase 3 positive cells per tumor highpowered field.



(A) IPA generated schematic of dysregulated c-Myc network in *Bves*<sup>-/-</sup>tumors compared to WT tumors. (B) c-Myc mRNA levels relative to WT colon.



Left: Representative images of immunohistochemistry for intratumoral phosphorylated serine 62 c-Myc staining. Right: Quantification of pS62 c-Myc positive cells per tumor high power field. High power fields were scored according to an index from 1-5 (a score of 1 denotes less than 20% of positive cells per high power field; a score of 2 denotes 20-40%; a score of 3 denotes 40-60%; a score of 4 denotes 60-80; a score of 5 denotes 80-100%). Each dot represents the average score of each mouse per tumor HPF. A minimum of 5 HPF were scored per mouse. Student's t test, \*p<0.05. Size standard=50 microns.



qPCR for c-Myc transcriptional target *Odc* in colons of WT and *Bves*<sup>-/-</sup> mice at baseline. \*p<0.05



qPCR of *BVES* mRNA in three human cell lines: HEK 293T, Human Corneal Epithelial (HCE), and Caco2.

### Human Corneal Epithelial cells

scr shBVES c-Myc

### **Supplementary Figure 7**

Immunoblot of c-Myc after knockdown of *BVES* in the Human Corneal Epithelial (HCE) cell line using shRNAs.



Relative luciferase values of HEK 293T cells co-transfected with an E2F2 reporter and an empty vector, HA-c-Myc and/or V5-BVES. Experiment was performed in technical triplicates and replicated twice. \*\*p<0.01



HEK 293T cells were transfected with HA:c-Myc and V5:BVES. V5:BVES was immunoprecipitated followed by immunoblotting for HA:c-Myc. Non-specific IgG was used as a control.

# **Supplementary Table 1**

					Distance to			Disease			
			biopsy		Dysplasia(f/	_		Duration(		Disease	Inflamma
Patient	Biopsy dx	UC NP/P	dx	Location	anal verge)	Age	Gender	mo.)	PSC?	Activity	tion
1	neg	NP	neg	distal		67	M	30	no		3-4+
2	neg	NP	neg	distal		70	F	16	no		3-4+
3	tumor	Р	tumor	distal	0 cm	55	F	20	no		4+
4	neg	NP	neg	distal		56	F	10	no		
5	tumor	Р	tumor	proximal	0 cm	47	M	8	no		?
6	tumor	Р	tumor	proximal	0 cm	31	М	10	no		?
7	neg	NP	neg	distal		48	М	9	no		3-4+
8	neg	Р	neg	distal		67	М	30	no		0
9	neg	NP	neg	distal		41	F	20	no		2-3+
10	neg	NP	neg	distal		63	М	39	no		
11	neg	NP	neg	distal		31	М	8	no		3-4+
12	neg	NP	neg	distal		49	F	20	no		1-2+
										marked	
13	HGD	Р	HGD	83 cm	0 cm	36	М	8	yes	activity	4+
				(C2)next to rectal							
14	HGD	Р	HGD	pieces	0 cm	53	F	NA	no?		4+
15	neg	NP	neg	7 cm		59	М	0.25		no data	active
16	neg	NP	neg	14 cm		51	F	20	no	no data	3+
17	neg	NP	neg	15 cm		46	F	17	no	no data	0
18	neg	Р	neg	3.4 cm	78.3 cm	36	М	11	yes	no data	0
										focal	
19	HGD	Р	HGD	92 cm	0 cm	58	М	29	yes	activity	0
20	HGD	Р	HGD	3 cm	0 cm	32	М	16	no	active	1+
			LGD+H							focal	
21	HGD	Р	GD	19 cm	0 cm	48	М	10	no	activity	0
										focal	
22	HGD	Р	HGD	4 cm	0 cm	33	М	13	no	active	4+
00				70.4	C dam to O d	<b>F</b> 4		10			4.
23				70.4 cm	6.4CM to CA	51		13	yes	active	1+
24	<u>HGD</u>		HGD	31.2 cm	U CM	33		22	no	no data	1+
25	neg	L P	neg	14.4 cm	18.4 cm	34	I M	17	yes	active	1+

# Supplementary Table 2

	UC Patients With Cancer (N=14)	UC Patients with Dysplasia (N=5)	UC patients (N=13)	Normal (N=11)
Average Age (sd)	51.4 + 18.3	53.2 + 15.5	55+10.2	60.9 + 11.5
Gender	6 Males, 8 Females	4 Males, 1 Female	8 Males, 5 Females	5 Males, 6 Females
BMI	26 + 9.2	n/a	n/a	26.6 + 3.1
Race	White (N=14)	n/a	n/a	Black (N=1), White (N=10)
Tumor Grade	Grade 1 (N=3), Grade 2 (N=2), Grade 3 (N=9)	n/a	n/a	n/a
Location if known	Descending (N=2), Transverse (N=2), Left (N=1), Ascending (N=1), Sigmoid (N=2), Rectum (N=4), Hepatic fixture (N=1)	n/a	n/a	n/a
Lymph Node Involvement	Positive (N=9), Negative (N=5)	n/a	n/a	n/a
Average Tumor Size	4.2 + 2.9 cm	n/a	n/a	n/a
Mesenteric Deposits	Absent(N=7), Present (N=8)	n/a	n/a	n/a